|
| From | To | Words | Weighted inclusion index | Inclusion index | Occurrences | Stability index |
|
| B-cell lymphoma, 2010–2015 | Helicobacter pylori infection, 2016–2021 | B-cell lymphoma | 0.15 | 0.25 | 104 | 0.01 |
| CagA, 2010–2015 | Helicobacter pylori, 2016–2021 | CagA; VacA | 0.57 | 0.25 | 274 | 0.01 |
| CagA, 2010–2015 | Helicobacter pylori infection, 2016–2021 | Genotypes; clinical-relevance | 0.18 | 0.25 | 78 | 0.01 |
| Helicobacter pylori, 2010–2015 | Helicobacter pylori, 2016–2021 | Helicobacter-pylori; expression; Escherichia-coli; identification; inflammation; protein; gene; cells; activation; in-vitro; epithelial-cells; colonization; gene-expression; pathogenesis; NF-kappa-b; growth; mice; inhibition; gastric epithelial-cells; apoptosis; diversity; crystal-structure; inflammatory-bowel-disease; acid; induction; binding; sequence; genes; system; mechanisms; oxidative stress; proteins; receptor; necrosis-factor-alpha; survival; DNA; mechanism; immune-response; virulence factors; virulence; secretion; iv secretion; T-cells; bacteria; vacuolating; cytotoxin; pathogenicity island; ulcerative-colitis; in-vivo; responses; urease; crohns-disease; pylori; helicobacter; evolution; gastric mucosa; phosphorylation; proliferation; pathway; mouse model; campylobacter-jejuni; metabolism; immune-responses; nitric-oxide; differentiation; dendritic cells; stress; regulatory T-cells; adhesion; model; E-cadherin; mycobacterium-tuberculosis; recognition; pseudomonas-aeruginosa; immunity; motility; Staphylococcus-aureus; rats; campylobacter; interleukin-8; translocation; recombination; derivatives; invasion | 0.82 | 0.01 | 2428 | 0.00 |
| Helicobacter pylori, 2010–2015 | Helicobacter pylori infection, 2016–2021 | Mucosa; pylori infection | 0.02 | 0.01 | 236 | 0.01 |
| Helicobacter pylori infection, 2010–2015 | Helicobacter pylori, 2016–2021 | Cancer; carcinogenesis; colorectal-cancer; breast-cancer; progression; hepatocellular-carcinoma; aberrant DNA methylation; DNA methylation | 0.09 | 0.01 | 697 | 0.01 |
| Helicobacter pylori infection, 2010–2015 | Helicobacter pylori infection, 2016–2021 | Helicobacter-pylori infection; risk; association; disease; carcinoma; gastric cancer; population; epidemiology; risk factors; stomach; intestinal metaplasia; peptic ulcer; adenocarcinoma; atrophic gastritis; classification; gastroesophageal-reflux disease; helicobacter-pylori eradication; nonsteroidal anti-inflammatory drugs; follow-up; united-states; antibodies; symptoms; prevention; stomach-cancer; mortality; polymorphisms; increased risk; diseases; lesions; body-mass index; barretts-esophagus; seroprevalence; cohort; irritable-bowel-syndrome; seropositivity; smoking; age; squamous-cell carcinoma; endoscopy; esophageal; obesity; atrophy; features; health; impact; trends | 0.72 | 0.01 | 1398 | 0.01 |
| Helicobacter pylori infection, 2010–2015 | Infection, 2016–2021 | Randomized controlled-trial; Japan | 0.01 | 0.02 | 94 | 0.01 |
| Infection, 2010–2015 | Helicobacter pylori infection, 2016–2021 | Prevalence; diagnosis; children; gastritis; duodenal ulcer; peptic-ulcer disease; transmission; adults; functional dyspepsia | 0.18 | 0.02 | 860 | 0.01 |
| InfecHion, 2010–2015 | Infection, 2016–2021 | Infection; eradication; management; meta-analysis; strains; therapy; antibiotic resistance; triple therapy; clarithromycin; resistance; susceptibility; metronidazole; omeprazole; amoxicillin; double-blind; efficacy; ulcer; mutations; eradication therapy; antimicrobial resistance; proton pump inhibitor; quadruple therapy; proton pump inhibitors; PCR; polymerase-chain-reaction; trial; consensus report; sequential therapy; clarithromycin resistance; guidelines; multicenter; lansoprazole; levofloxacin; c-13-urea breath test; antimicrobial susceptibility | 0.91 | 0.02 | 2027 | 0.01 |
|
